Medy-Tox Inc Asset Resilience Ratio

Latest as of September 2025: 0.04%

Medy-Tox Inc asset resilience ratio. Medy-Tox Inc (086900) has an Asset Resilience Ratio of 0.04% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 086900 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩252.96 Million
≈ $171.43K USD Cash + Short-term Investments

Total Assets

₩586.91 Billion
≈ $397.74 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Medy-Tox Inc (2013–2024)

Asset resilience ratio of Medy-Tox Inc from 2013 to 2024. This chart shows how Medy-Tox Inc's Asset Resilience Ratio has changed over time. Read Medy-Tox Inc total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Medy-Tox Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Medy-Tox Inc asset portfolio.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩252.96 Million 0.04%
Total Liquid Assets ₩252.96 Million 0.04%

Asset Resilience Insights

  • Limited Liquidity: Medy-Tox Inc maintains only 0.04% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Medy-Tox Inc Industry Peers by Asset Resilience Ratio

Compare Medy-Tox Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Ascendis Pharma AS
F:A71
Biotechnology 0.00%
Abivax SA
PA:ABVX
Biotechnology 2.58%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Disc Medicine Inc.
NASDAQ:IRON
Biotechnology 84.22%
Alpha Tau Medical Ltd
NASDAQ:DRTS
Biotechnology 65.79%
Galapagos N.V.
AS:GLPG
Biotechnology 86.45%

Medy-Tox Inc Asset Resilience Ratio by Year (2013–2024)

Medy-Tox Inc asset resilience ratio by year from 2013 to 2024. The table below shows the annual Asset Resilience Ratio data for Medy-Tox Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 9.59% ₩59.00 Billion
≈ $39.98 Million
₩615.16 Billion
≈ $416.89 Million
+4.15pp
2023-12-31 5.44% ₩33.27 Billion
≈ $22.55 Million
₩611.62 Billion
≈ $414.49 Million
+1.05pp
2022-12-31 4.39% ₩26.19 Billion
≈ $17.75 Million
₩596.29 Billion
≈ $404.10 Million
-9.79pp
2021-12-31 14.18% ₩81.92 Billion
≈ $55.52 Million
₩577.70 Billion
≈ $391.50 Million
+2.29pp
2020-12-31 11.89% ₩55.61 Billion
≈ $37.68 Million
₩467.76 Billion
≈ $317.00 Million
+6.31pp
2019-12-31 5.58% ₩23.51 Billion
≈ $15.93 Million
₩421.53 Billion
≈ $285.66 Million
-0.85pp
2018-12-31 6.42% ₩25.38 Billion
≈ $17.20 Million
₩395.01 Billion
≈ $267.70 Million
-2.33pp
2017-12-31 8.76% ₩33.36 Billion
≈ $22.61 Million
₩380.95 Billion
≈ $258.16 Million
-0.66pp
2016-12-31 9.42% ₩30.53 Billion
≈ $20.69 Million
₩324.03 Billion
≈ $219.59 Million
-15.03pp
2015-12-31 24.45% ₩49.77 Billion
≈ $33.73 Million
₩203.55 Billion
≈ $137.94 Million
-22.76pp
2014-12-31 47.21% ₩79.55 Billion
≈ $53.91 Million
₩168.51 Billion
≈ $114.20 Million
+29.21pp
2013-12-31 18.00% ₩14.30 Billion
≈ $9.69 Million
₩79.41 Billion
≈ $53.82 Million
--
pp = percentage points

About Medy-Tox Inc

KQ:086900 Korea Biotechnology
Market Cap
$315.20 Million
₩465.12 Billion KRW
Market Cap Rank
#14331 Global
#432 in Korea
Share Price
₩70700.00
Change (1 day)
+10.64%
52-Week Range
₩62600.00 - ₩138600.00
All Time High
₩671543.08
About

Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more